Originally Aired: February 25, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
It is well established for decades that vaccination is one of the most powerful and economical tools against potentially lethal infectious diseases. According to the World Health Organization (WHO), up to 3 million human lives are saved each year due to vaccination. It not only has a major impact on the development of countries and populations, but it is more and more admitted that vaccination plays a key role in the fight against resistance to antibiotics.
Although manufactured for decades, the technology of vaccine development has seen recent significant improvements and new vaccine modalities are on the rise. In particular, the purification process requires specific solutions tailored towards each unique molecule type. Additionally, the recent COVID-19 pandemic has highlighted the need for innovative, flexible, and reliable purification solutions, immediately available in large amounts and fully compatible with GMP manufacturing.
Join this GEN webinar and learn more on novel purification solutions that can help accelerate early vaccine candidate screening and improve the downstream process of different vaccine modalities such as mRNA, recombinant proteins, and Virus-Like Particles (VLPs). In addition, a new scavenging method for the removal of Baculovirus process impurities will be presented.
• Understand the benefits of implementing affinity chromatography into a vaccine production process.
• Find out more on the C-tag technology, allowing for easy vaccine candidate screening during development.
• Discover how novel affinity chromatography resins can help to improve the purification process of new vaccine modalities such as mRNA- or protein-based vaccines or viral vectors.
• Learn more on a new scavenging chromatography resin, specifically developed for the removal of Baculovirus process impurities.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Webinar produced with support from: